Hereditary angioedema with C1Inh deficiency
MONDO:0033946Forms of hereditary angioedema that occur due to mutations in the gene for complement C1 inhibitor protein. Type I hereditary angioedema is associated with reduced serum levels of complement C1 inhibitor protein. Type II hereditary angioedema is associated with the production of a non-functional complement C1 inhibitor protein.
Also known as: angioedema, hereditary, 1 and 2, angioedema, hereditary, type 1/2, C1 esterase inhibitor, deficiency of, HAE1, angioedema, hereditary, type 1, angioedema, hereditary, type 2, angioedema, hereditary, type I, angioneurotic edema, hereditary
32 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
-
CRISPR therapy takes on rare swelling disorder
Disease control OngoingThis phase 3 trial tests a one-time gene editing treatment called NTLA-2002 for people with hereditary angioedema (HAE), a rare genetic condition causing sudden, painful swelling attacks. About 80 participants will receive either the treatment or a placebo. The goal is to see if …
Phase: PHASE3 • Sponsor: Intellia Therapeutics • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New shot could stop dangerous swelling attacks in HAE
Disease control OngoingThis Phase 3 trial tests whether navenibart, a drug given as a shot under the skin, can prevent attacks in people with hereditary angioedema (HAE). About 145 adults and teens with HAE type 1 or 2 will receive either navenibart or a placebo for 6 months. The main goal is to see if…
Phase: PHASE3 • Sponsor: Astria Therapeutics, Inc. • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
New hope for HAE patients: experimental drug aims to slash attack rate
Disease control OngoingThis study tests an experimental drug called BW-20805 in 25 adults with hereditary angioedema (HAE), a condition that causes sudden, painful swelling. The goal is to see if the drug can reduce how often attacks happen over about 6 months. Participants must have had at least 2 att…
Phase: PHASE2 • Sponsor: Shanghai Argo Biopharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
New drug shows promise in preventing hereditary swelling attacks
Disease control OngoingThis study tests the long-term safety and effectiveness of donidalorsen, a drug given as a shot under the skin, to prevent attacks of hereditary angioedema (HAE). HAE causes sudden, painful swelling in various body parts. The trial involves 154 participants who previously complet…
Phase: PHASE3 • Sponsor: Ionis Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New pill could stop dangerous swelling attacks in hereditary angioedema
Symptom relief ENROLLING_BY_INVITATIONThis study tests a pill called deucrictibant for quickly treating swelling attacks in people with hereditary angioedema (HAE), including life-threatening throat swelling. About 150 adults who have had HAE attacks before will take the drug as needed and be monitored for safety and…
Phase: PHASE2, PHASE3 • Sponsor: Pharvaris Netherlands B.V. • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Real-World data on HAE drug lanadelumab: does it cut attacks?
Knowledge-focused OngoingThis study follows 50 people in the UK with hereditary angioedema (HAE) types I or II who are taking lanadelumab. Researchers will compare the number of HAE attacks in the year before starting the drug to up to two years after. The goal is to see how well the drug works outside o…
Sponsor: Takeda • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC